2. Induced Disease Models Products Cell Cycle/DNA Damage Apoptosis Autophagy
  3. Urinary System Disease Models DNA Alkylator/Crosslinker Ferroptosis Autophagy
  4. Cisplatin

Cisplatin  (Synonyms: cis-Platinum; CDDP; cis-Diaminodichloroplatinum)

Cat. No.: HY-17394 Purity: 99.84%
COA Handling Instructions

Molarity Calculator

Cisplatine (CDDP) est un agent de chimiothérapie antinéoplasique par réticuler avec ADN et induire des dommages à l'ADN dans les cellules cancéreuses. Cisplatine active la ferroptose et induit l'autophagie.

Cisplatin (CDDP) ist ein antineoplastisches Chemotherapeutikum, das mit DNA vernetzt ist und DNA-Schäden in Krebszellen verursacht. Cisplatin aktiviert die ferroptosis und induziert die autophagy.

Cisplatin (CDDP) is an antineoplastic chemotherapy agent by cross-linking with DNA and causing DNA damage in cancer cells. Cisplatin activates ferroptosis and induces autophagy.

For research use only. We do not sell to patients.

Cisplatin Chemical Structure

Cisplatin Chemical Structure

CAS No. : 15663-27-1

Size Price Stock Quantity
5 mg USD 25 In-stock
10 mg USD 35 In-stock
50 mg USD 45 In-stock
100 mg USD 60 In-stock
500 mg USD 120 In-stock
1 g   Get quote  
5 g   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 395 publication(s) in Google Scholar

Cisplatin Related Antibodies

Top Publications Citing Use of Products

383 Publications Citing Use of MCE Cisplatin

WB
IF

    Cisplatin purchased from MedChemExpress. Usage Cited in: Gut Microbes. 2023 Jan-Dec;15(1):2197836.  [Abstract]

    Cisplatin (CDDP; 3.33 μM or 1.67 μM; 96 h) suppresses the proliferation of ECA-109 and KYSE-150 cells (3.33 μM 1 μg/ml in ECA-109 cells, 1.67 μM 0.5 μg/ml in KYSE-150 cells).

    Cisplatin purchased from MedChemExpress. Usage Cited in: Gut Microbes. 2023 Jan-Dec;15(1):2197836.  [Abstract]

    Cisplatin (CDDP; 3.33 μM or 1.67 μM; 96 h) increases the protein expression of p53 and p21 in ECA-109 and KYSE-150 cells (3.33 μM 1 μg/ml in ECA-109 cells, 1.67 μM 0.5 μg/ml in KYSE-150 cells).

    Cisplatin purchased from MedChemExpress. Usage Cited in: Biochem Biophys Res Commun. 2023 May 20.

    Cisplatin (25, 50 μM; 24 h) significantly increases the expression of caspase-3 in PK-15 cells.

    Cisplatin purchased from MedChemExpress. Usage Cited in: Nat Commun. 2019 Aug 21;10(1):3761.  [Abstract]

    IB analysis of the level of cleaved-caspase 3 and cleaved-PARP1 in the indicated chemotherapy-treated xenograft tumors. GAPDH served as the loading control.

    Cisplatin purchased from MedChemExpress. Usage Cited in: Nat Commun. 2019 Aug 21;10(1):3761.  [Abstract]

    Genotoxic stress-induced β-catenin signaling is activated via a TCF- or FOXO-independent mechanism. Representative images of the subcellular localization of β-catenin in the indicated cells treated with CPT (10 μM, 1 h), IR (10 Gy), and CDDP (10 μM, 1 h), as analyzed by immunofluorescence staining.

    Cisplatin purchased from MedChemExpress. Usage Cited in: Cancer Res. 2018 Oct 1;78(19):5694-5705.  [Abstract]

    WT and S47 E1A/RAS cells are treated with 10μM CDDP for 24 hours in the presence or absence of the protein synthesis inhibitor Cycloheximide (2.5 g/mL). Cell lysates are subjected to Western blot analysis, and immunoblotted for cleaved caspase-3, p53, p21, and HSP90 (loading control). CDDP: cisplatin

    Cisplatin purchased from MedChemExpress. Usage Cited in: Cancer Res. 2018 Oct 1;78(19):5694-5705.  [Abstract]

    WT and S47 E1A/RAS cells are treated with 10 M Cisplatin (CDDP) for 24 hours. Cells are then fractionated into three fractions: whole cell lysate (W), mitochondria (M), and cytosol (C).

    Cisplatin purchased from MedChemExpress. Usage Cited in: Oncol Lett. 2018 Feb;15(2):2583-2589.  [Abstract]

    MLN4924 increases CDDP induced apoptosis of esophageal cancer cells. EC1 and Kyse450 cells are treated with 1.6 μg/mL CDDP alone or in combina¬tion with 0.3 μM MLN for 72 h. Cleaved PARP are detected by western blotting.

    Cisplatin purchased from MedChemExpress. Usage Cited in: Oncol Lett. 2018 May;15(5):6469-6474.  [Abstract]

    MDA-MB-231 cells are grown and treated with CC-5013 (Len), Cisplatin (Cis), or their combination for 72 h and then subjected to western blot analysis.

    Cisplatin purchased from MedChemExpress. Usage Cited in: Neurosci Lett. 2018 Aug 24;682:112-117.  [Abstract]

    After treatment of CDDP with or without the autophagy inhibitor CQ, the expression of LC3-II in the CQ+CDDP group is less than that in the CQ group but is higher than that in the CDDP group at 24 h and 96 h.

    Cisplatin purchased from MedChemExpress. Usage Cited in: Cell Signal. 2017 May 1;36:108-116.  [Abstract]

    PAQR3 affects DNA damage repair. AGS cells are treated with different doses of VP-16 (for 24 h), Cisplatin (for 24 h) and NSC 123127 (for 10 h) as indicated, followed by immunoblotting with the antibodies.

    Cisplatin purchased from MedChemExpress. Usage Cited in: Oncotarget. 2017 Apr 25;8(17):29125-29137.  [Abstract]

    Knockdown of ROC1 significantly enhances CDDP-induced apoptosis. TE1 and Kyse450 cells are transfected with siROC1 for 48 h and then treated with 1 μg/mL CDDP for 48 h. Knockdown efficiency and cleaved PARP are assessed by western blotting analysis. Protein expression is quantified and statically analyzed.

    • Biological Activity

    • Protocol

    • Purity & Documentation

    • References

    • Customer Review

    Description

    Cisplatin (CDDP) is an antineoplastic chemotherapy agent by cross-linking with DNA and causing DNA damage in cancer cells. Cisplatin activates ferroptosis and induces autophagy[1][2][3].

    IC50 & Target

    DNA Alkylator/Crosslinker[1]
    In Vitro

    Cisplatin (CDDP) causes apoptosis of HeLa cells in a dose-dependent manner, with a concentration of 30 μM Cisplatin resulting in death of greater than 90% of the cell population by 24 h of treatment. The kinetics of Cisplatin-induced apoptosis are examined using a 30 μM concentration. Cisplatin Activates the MEK/ERK Signaling Pathway, 20 and 30 μM Cisplatin, both of which results in significant apoptosis, leads to strong activation of ERK[1].
    Cisplatin (50 μM) produces time-dependent apoptosis in renal proximal tubular cell (RPTCs), causing cell shrinkage, a 50-fold increase in caspase 3 activity, a 4-fold increase in phosphatidylserine externalization, and 5- and 15-fold increases in chromatin condensation and DNA hypoploidy, respectively[2].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Cisplatin Related Antibodies
    In Vivo

    In melanoma-bearing mice, Cisplatin (CDDP; 4 mg/kg B.W.) reduces the size and weight of the solid tumors, and HemoHIM supplementation with Cisplatin enhances the decrease of both the tumor size and weight[3].
    Cisplatin administration results in significant increases in the kidney weight as a percentage of the total body weight, urine volume, serum creatinine, and blood urea nitrogen by about 132, 315, 797, and 556% in comparison with the control rats, respectively[4].
    Induction of Acute Kidney Injury (AKI)[7][8]
    Background
    The pathogenesis of Cisplatin-induced acute kidney injury (AKI) is complex and Oxidative stress, mitochondrial dysfunction, inflammation, and apoptosis are all participating in the progression of Cisplatin-induced AKI.Oxidative stress is a predominant mechanism of injury in cisplatin-induced AKI.
    Specific Mmodeling Methods
    Mice: C57BL/6 • male • 6-week-old (period: 2 weeks)
    Administration: 5 mg/kg • ip • once daily for 2 weeks
    Note
    (1) Suggest using male mice as female mice are more resistant to renal injury.
    (2) Mice can be deprived of food and water for 18 h prior to induction, and food and water are returned after administration.
    (3) Cisplatin can be dissolved in sterile saline solution to prepare injection working solution while protecting from light.


    Modeling Indicators
    Molecular changes: Increased indicators: Serum creatinine (SCr) levels, blood urea nitrogen (BUN) levels, neutrophil gelatinase-associated lipocalin (NGAL), 3-nitrotyrosine.
    Correlated Product(s): 84-B10 (HY-44307)
    Opposite Product(s):

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
    Clinical Trial
    Molecular Weight

    300.05

    Formula

    Cl2H6N2Pt
    CAS No.
    Appearance

    Solid

    Color

    Light yellow to yellow

    SMILES

    Cl[Pt](Cl)([NH3])[NH3]
    Shipping

    Room temperature in continental US; may vary elsewhere.
    Storage

    4°C, protect from light

    *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

    Solvent & Solubility
    In Vitro: 

    DMF : 14.17 mg/mL (47.23 mM; Need ultrasonic and warming; DMSO can inactivate Cisplatin's activity)

    H2O : 1 mg/mL (3.33 mM; ultrasonic and warming and heat to 60°C; DMSO can inactivate Cisplatin's activity)

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 3.3328 mL 16.6639 mL 33.3278 mL
    5 mM 0.6666 mL 3.3328 mL 6.6656 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    * Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo:

    For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  PBS

      Solubility: 0.91 mg/mL (3.03 mM); Clear solution; Need ultrasonic and warming and heat to 60°C

    • Protocol 2

      Add each solvent one by one:  50% PEG300    50% Saline

      Solubility: 10 mg/mL (33.33 mM); Suspended solution; Need ultrasonic

    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Calculation results:
    Working solution concentration: mg/mL
    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).
    Purity & Documentation

    Purity: 99.84%

    COA (247 KB) RP-HPLC (258 KB) Elemental Analysis Report (105 KB)

    Handling Instructions (2659 KB)
    References
    Cell Assay
    [1]

    HeLa and A549 cells are maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum, 100 units of Penicillin, and 100 μg of Streptomycin/mL. They are cultured at 37°C in a humidified chamber containing 5% CO2. For the induction of apoptosis, cells are plated in 60-mm dishes 1 day prior to Cisplatin (0-30 μM) treatment[1].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.
    Animal Administration
    [3][4]

    Mice[3]
    Mice are divided randomly into three groups (Control, Cisplatin and Cisplatin+HemoHIM), and each group consists of twenty mice. B16F0 melanoma (5×105 cells/mouse) is inoculated into subcutaneous femoral left region of mice at 3 days before an initial injection of Cisplatin. Cisplatin is injected intraperitoneally at 4 mg/kg body weight (B.W.) on day 0, 7 and 14 (total three injections). Experimental group is intubated with HemoHIM at a final concentration of 100 mg/kgB.W. by everyday from day -1 to day 16, while the control group received only water. On day 17 after initial injection of Cisplatin, all mice of each group are experimented, respectively, to evaluate tumor weight or tumor size. The tumor size is calculated as follows: tumor size=ab2/2, where a and b are the larger and smaller diameters, respectively.
    Rats[4]
    Male Sprague-Dawley rats weighing 200 to 250 g are divided at random into 4 groups of 4 or 5 animals each. The first group (control) received a vehicle (5% carboxymethyl cellulose sodium solution (CMC-Na), 5 mL/kg body wt., p.o.) used for Capsaicin (Cap). The second group received Cap (10 mg/kg/d, p.o.) in 5% CMC-Na (5 mL/kg), and the third received 5% CMC-Na for 6 consecutive days injected with Cisplatin (5 mg/kg in physiological saline solution, i.p.). The fourth group received Cap (10 mg/kg/d, p.o.) in 5% CMC-Na for 6 consecutive days after Cisplatin injection (5 mg/kg, i.p.). For all groups, Cap or vehicle is given twice daily. The selected Cap concentration and the dose administration schedule without inducing any rat intestinal damage are chosen using data from our preliminary experiments.

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.
    References

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    H2O / DMF 1 mM 3.3328 mL 16.6639 mL 33.3278 mL 83.3195 mL
    DMF 5 mM 0.6666 mL 3.3328 mL 6.6656 mL 16.6639 mL
    10 mM 0.3333 mL 1.6664 mL 3.3328 mL 8.3319 mL
    15 mM 0.2222 mL 1.1109 mL 2.2219 mL 5.5546 mL
    20 mM 0.1666 mL 0.8332 mL 1.6664 mL 4.1660 mL
    25 mM 0.1333 mL 0.6666 mL 1.3331 mL 3.3328 mL
    30 mM 0.1111 mL 0.5555 mL 1.1109 mL 2.7773 mL
    40 mM 0.0833 mL 0.4166 mL 0.8332 mL 2.0830 mL

    * Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    Cisplatin Related Classifications

    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    Cisplatin15663-27-1cis-Platinum CDDP cis-DiaminodichloroplatinumDNA Alkylator/CrosslinkerFerroptosisAutophagyantineoplasticchemotherapydrugcross-linkingDNAdamageInhibitorinhibitorinhibit

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Salutation

    Applicant Name *

    		 

    Email Address *

    Phone Number *

    		 

    Organization Name *

    Department *

    		 

    Requested quantity *

    Country or Region *

    		      

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Cisplatin
    Cat. No.:
    HY-17394
    Quantity:
    MCE Japan Authorized Agent:

    Customer Review

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Lot #

    Applicant Name *

    		 

    Email Address *

    Phone Number

    		 

    Department *

    Organization Name *

    		 

    Country or Region *

    Remarks

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.